Journal Article

Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL

Oran, B, Ledesma, C, Anderlini, P, Popat, U R, Bassett, R L, Alatrash, G, Ferrajoli, A, Ahmed, S, Sui, D, Turturro, F, Medeiros, L J, Kadia, T M, Burger, J A, Ciurea, S O, Olson, A, Jorgensen, J L, Marin, D, Jabbour, E J, Khouri, I F, Gulbis, A M, Samuels, B I, Patel, K K

2017

Overview

Bendamustine has shown a favorable safety profile when included in chemotherapy regimens for several types of lymphoma, including CLL. This study investigated the long-term effect of adding bendamustine to a conditioning regimen on survival, rate of engraftment, immune recovery and GvHD after allogeneic stem cell transplantation (alloSCT) in CLL patients. These outcomes were compared with the fludarabine, cyclophosphamide and rituximab (FCR) conditioning regimen. We reviewed the data for 89 CLL patients treated on three trials at our institution. Twenty-six (29%) patients received bendamustine, fludarabine and rituximab (BFR) and 63 (71%) received FCR. Patient characteristics were similar in both groups. Ten (38%) BFR-treated patients vs only two (3%) FCR-treated patients did not experience severe neutropenia ( P =<0.001). The 3-year overall survival estimates for the BFR and FCR groups were 82 and 51% ( P =0.03), and the 3-year PFS estimates were 63% and 27% ( P =0.001), respectively. The 2-year treatment-related mortality was 8 and 23% and the incidence of grade 3 or 4 GvHD was 4% and 10%, respectively. This study is the first to report that addition of bendamustine to alloSCT conditioning for CLL patients is associated with improved survival and lower mortality, myelosuppression, and GvHD.

• Publisher: Nature Publishing Group UK,Nature Publishing Group
• Subject: 631/67 / Adult / Aged / Bendamustine / Bendamustine Hydrochloride - administration & dosage / Bone marrow / Bone marrow transplantation / Care and treatment / Cell Biology / Cyclophosphamide - administration & dosage / Disease-Free Survival / Dosage and administration / Female / Health aspects / Hematology / Humans / Internal Medicine / Leukemia / Leukemia, Lymphocytic, Chronic, B-Cell - mortality / Leukemia, Lymphocytic, Chronic, B-Cell - therapy / Male / Medicine / Medicine & Public Health / Middle Aged / original-article / Public Health / Rituximab - administration & dosage / Stem cell transplantation / Stem Cells / Survival Rate / Transplantation Conditioning - methods / Vidarabine - administration & dosage / Vidarabine - analogs & derivatives